Adverse cutaneous reactions to antidepressants

American Journal of Clinical Dermatology

Volumn 3, Issue 5, 2002, Pages 329-339

  Warnock, J K ^a   Morris, D W ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TULSA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PIPERAZINE DERIVATIVE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ACNE; ALLERGIC VASCULITIS; ALOPECIA; ANGIONEUROTIC EDEMA; CLINICAL FEATURE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; ERYTHRODERMA; EXFOLIATIVE DERMATITIS; HUMAN; HYPERHIDROSIS; NEGRO; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEBORRHEIC DERMATITIS; SERUM SICKNESS; SEX DIFFERENCE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 0036310617     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203050-00005     Document Type: Review

References (88)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the US: Results from the National Comorbidity Survey
2. Guidelines of care for cutaneous adverse drug reactions: American Academy of Dermatology
3. Dermatological side effects with psychotropics
4. Drug-induced cutaneous reactions: A report from the Boston Collaborative Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982
5. Cutaneous drug reactions, clinical types and causative agents: A five-year study of in-patients (1981-1985)
6. Epidemiology of adverse cutaneous reactions to drugs
7. Desipramine-related slate-gray skin pigmentation
8. Drug-related alopecia in patients treated with tricyclic antidepressants
9. Desipramine-induced blue-gray photosensitive pigmentation
10. Hypersensitivity reaction to desipramine
11. Synergism of minocycline and amitriptyline in cutaneous hyperpigmentation
12. Hypersensitivity syndrome caused by amitriptyline administration
13. Clomipramine-induced pseudocyanotic pigmentation
14. Imipramine-induced alopecia areata-like lesions
15. Imipramine-induced hyperpigmentation: Four cases and a review of the literature
16. Imipramine hyperpigmentation: A slate-gray discoloration caused by long-term imipramine administration
17. Laser treatment of imipramine-induced hyperpigmentation
18. Critical overview: Adverse cutaneous reactions to psychotropic medications
19. Anticonvulsant hypersensitivity syndrome: Incidence, prevention and management
20. Amoxapine: A cause of toxic epidermal necrolysis?
21. Photosensitivity reaction to fluoxetine
22. Fluvoxamine photosensitivity
23. The side effect profile and safety of fluoxetine
24. Fluoxetine-induced psoriasis
25. The safety of fluoxetine: An update
26. A case of fluoxetine-induced serum sickness
27. Bupropion-induced erythema multiforme
28. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine
29. Bupropion-induced serum sickness-like reaction
30. Serum sickness-like reaction to bupropion
31. Serum sickness induced by bupropion
32. Bupropion hydrochloride induced serum sickness-like reaction
33. Generalized pustular psoriasis precipitated by trazodone in the treatment of depression
34. Severe adverse cutaneous reactions to drugs
35. Maprotiline-induced acne
36. Cutaneous vasculitis from maprotiline
37. Leukocytoclastic vasculitis secondary to trazodone treatment
38. Lethal hepatic necrosis after therapy with imipramine and desipramine
39. Photosensitivity and thrombocytopenia due to amitriptyline
40. Possible mechanisms of toxicity due to photochemical products of protriptyline
41. A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features
42. Photosensitive reaction to phenelzine: A case report
43. Hair loss during fluoxetine treatment
44. Hair loss associated with fluoxetine
45. Hair loss associated with fluoxetine but not with citalopram
46. Hair loss associated with fluoxetine use in two family members
47. Hair loss associated with fluoxetine treatment
48. Severe hair loss associated with fluoxetine use
49. Two cases of hair loss after sertraline use
50. Fluoxetine associated paresthesias and alopecia in a woman who tolerated sertraline
51. Hair loss associated with fluvoxamine use
52. Desipramine and cutaneous reactions in pediatric outpatients
53. Antidepressants in the treatment of attention-deficit/hyperactivity disorder
54. Bupropion-induced serum sickness-like reaction
55. Toleration and safety of sertraline: Experience worldwide
56. Imipramine side effects in children
57. True and apparent side effects in a controlled trial of chlorpromazine and imipramine in depression
58. A controlled double-blind study comparing binedaline and imipramine in the treatment of endogenous depression
59. Depression associated with alcohol withdrawal: Imipramine therapy compared with placebo
60. A comparison between daily and nightly dose regimen of amitriptyline and maprotiline (Ludiomil) in the treatment of reactive depression in general practice
61. Allergic skin eruption with desipramine treatment
62. Drug eruption secondary to trazodone
63. Trazodone in the treatment of depressed inpatients
64. Once daily dosage with maprotiline (Ludiomil)
65. Maprotiline: A double-blind study of a new tetracyclic antidepressant in severe depression
66. Double-blind comparison of maprotiline with amitriptyline in the treatment of depressive illness
67. Information on adverse reactions to drugs
68. Cutaneous reactions to imipramine and chlordiazepoxide
69. Severe neutropenia and urticaria with antidepressant therapy
70. Long-term therapy for depression with trazodone
71. Postmarketing surveillance by patient self-monitoring: Trazodone versus fluoxetine
72. Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients
73. Fixed drug eruption: A brief review
74. Photosensitivity associated with antipsychotics, antidepressants, and anxiolytics
75. Dermatologic side effects of psychopharmacologic agents
76. Drug-induced alopecia
77. Psychotropic medication and drug-related alopecia
78. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
79. Allergic reactions to drugs and biologic agents
80. Serious and life-threatening drug eruptions
81. Adverse cutaneous reactions to psychotropic drugs
82. Adverse cutaneous reactions to antidepressants